Family history influences the tumor characteristics and prognosis of breast cancers developing during postmenopausal hormone therapy
- 10 October 2017
- journal article
- research article
- Published by Springer Nature in Familial Cancer
- Vol. 17 (3) , 321-331
Abstract
Long term use of postmenopausal hormone therapy (HT) has been reported to increase breast cancer risk. On the other hand, observational studies suggest that breast cancers diagnosed during HT may have a more favorable prognosis. While family history is a risk factor for breast cancer, and genetic factors also influence prognosis, the role of family history in combination with HT use has been little studied. We investigated the relationship between HT, family history, and prognosis in 584 (267 exposed) familial and 952 (460 exposed) non-familial breast cancer cases, using three survival end points: death from breast cancer (BCS), distant disease free survival (DDFS), and local recurrence free survival (LRFS). Among non-familial cases, HT was associated with better BCS (HR 0.63, 95% CI 0.41–0.94; p = 0.025), and DDFS (HR 0.58, 95% CI 0.40–0.85; p = 0.005), with a consistent but not statistically significant effect in LRFS. This effect was not seen in familial cases (HR > 1.0), and family history was found to interact with HT in BCS (p(interaction) = 0.0067) (BC-death) and DDFS (p(interaction) = 0.0070). There was phenotypic heterogeneity between HT-associated tumors in familial and non-familial cases, particularly on estrogen receptor (ER) status, although the interaction between HT and family history appears to be at least partially independent of these markers (p = 0.0370 after adjustment for standard prognostic factors). If confirmed by further studies, our results suggest that family history should be taken into consideration in clinical counseling before beginning a HT regimen.Keywords
Funding Information
- Sigrid Juséliuksen Säätiö
- Terveyden Tutkimuksen Toimikunta (266528)
- Helsinki University Central Hospital Research Fund
- Finnish Cancer Society
This publication has 36 references indexed in Scilit:
- NORDCAN – a Nordic tool for cancer information, planning, quality control and researchActa Oncologica, 2010
- Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort studyBreast Cancer Research, 2008
- Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancerBreast Cancer Research and Treatment, 2008
- Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapyAmerican Journal of Obstetrics and Gynecology, 2007
- The influence of hormone replacement therapy on the pathology of breast cancerEuropean Journal of Surgical Oncology, 2005
- Familial breast cancer in southern FinlandEuropean Journal of Cancer, 2000
- Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancerInternational Journal of Cancer, 1998
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- Prognostic characteristics in breast cancers after hormone replacement therapyBreast Cancer Research and Treatment, 1996
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991